Clinical Trials Browser

Phase 1 × Terminated × Temozolomide × Clear all

NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase 1 Terminated

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

NCT04239092 2025-07-17

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Phase 1 Terminated

Diffuse Intrinsic Pontine Glioma, Meningioma, Neoplasms, Neuroblastoma

NCT01430351 2025-05-07

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Phase 1 Terminated

Glioblastoma, Gliosarcoma

NCT04397679 2025-01-15

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

Phase 1 Terminated

Glioblastoma, Gliosarcoma

NCT04525014 2024-10-31

PIRATE

Phase 1 Terminated

Brain Neoplasms, Neoplasms, Spinal Cord Neoplasms, Central Nervous System Neoplasms

NCT01127178 2024-10-10

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Phase 1 Terminated

12 enrolled 13 charts

Other solid neoplasm

Solid Tumors

NCT04324840 2024-07-26

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Phase 1 Terminated

Metatropic dwarfism, Glioblastoma

NCT02880410 2024-04-12

FLAG

Phase 1 Terminated

Glioblastoma

NCT03705351 2024-03-04

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Phase 1 Terminated

7 enrolled 12 charts

Brain Neoplasms, Glioblastoma

NCT02168270 2023-11-24

Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma

Phase 1 Terminated

4 enrolled 6 charts

Astrocytoma, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT02530502 2023-11-18

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1 Terminated

Glioblastoma

NCT01700569 2023-02-21

FOLAGLI

Phase 1 Terminated

Glioblastoma, Glioma

NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Phase 1 Terminated

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02864368 2022-06-09

PERFORMANCE

Phase 1 Terminated

27 enrolled 13 charts

Glioblastoma

NCT03246113 2019-08-13

Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

Phase 1 Terminated

Glioblastoma

NCT00915694 2019-04-23

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

Phase 1 Terminated

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01284335 2019-01-10

A Safety Study in Participants With Advanced Solid Tumors

Phase 1 Terminated

234 enrolled 23 charts

Neoplasm Metastasis

NCT00734526 2018-11-09

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 1 Terminated

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00895960 2018-11-08

Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma

Phase 1 Terminated

Brain Diseases, Central Nervous System Diseases, Glioblastoma, Gliosarcoma

NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Phase 1 Terminated

4 enrolled 8 charts

CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

NCT02254954 2018-02-27

Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma

Phase 1 Terminated

Glioblastoma

NCT02510950 2017-11-17

Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

Phase 1 Terminated

Glioblastoma

NCT01067066 2017-07-21

A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

Phase 1 Terminated

Melanoma

NCT01409174 2017-05-31

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase 1 Terminated

Melanoma, Neoplasm Metastasis

NCT00437957 2017-02-23

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

Phase 1 Terminated

Brain Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

Neoplasms

NCT00629187 2012-04-27

CN-306

Phase 1 Terminated

BreastCNSDermatologicThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Central Nervous System Neoplasms, Neoplasms, Second Primary

NCT00515788 2012-03-12

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Phase 1 Terminated

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT00508456 2012-01-16

Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM

Phase 1 Terminated

Glioblastoma

NCT00516282 2011-08-26

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

Phase 1 Terminated

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00003567 2010-06-11

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1 Terminated

CNSLymphoidOther hematologic neoplasmSarcoma

Astrocytoma, Brain Neoplasms, Burkitt Lymphoma, Ependymoma, Glioblastoma, Glioma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Oligodendroglioma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00272415 2009-03-11

A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

Phase 1 Terminated

Deafness, Autosomal Recessive 53, Melanoma